Data completeness
2/8 — Basic
DYNAPEN (dicloxacillin sodium) by Bristol Myers Squibb is clinical pharmacology microbiology mechanism of action penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. Approved for the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.
Drug data last refreshed 4w ago
Mechanism of Action
CLINICAL PHARMACOLOGY Microbiology Mechanism of Action Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall. Antibacterial Activity…
Indications (1)
Worked on DYNAPEN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.